AKT1 and gastric cancer: Similar inhibitory effects on this pathway have been demonstrated in other gastric cancer models, such as Bufalin treatment (46, 47), and in related tumor studies involving TRIM59 suppression (48) and ILF3 overexpression (49), further reinforcing the critical role of the PI3K/Akt/mTOR axis in maintaining aberrant tumor metabolism.